Evidence map›Paper›PMID 37184249›Full record

ArticleRapid communications in mass spectrometry : RCM2023

Development and validation of an ultrahigh-performance liquid chromatography-tandem mass spectrometry method to investigate the plasma pharmacokinetics of a K

Mohammad Asikur Rahman, Devaraj Venkatapura Chandrashekar, Young-Woo Nam, Basir Syed, David Salehi, Hamidreza Montazeri Aliabadi, Miao Zhang, Reza Mehvar

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rapid communications in mass spectrometry : RCM, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mohammad Asikur RahmanDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, California, USA.
Devaraj Venkatapura ChandrashekarDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, California, USA.
Young-Woo NamDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, California, USA.
Basir SyedDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, California, USA.
David SalehiDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, California, USA.
Hamidreza Montazeri AliabadiDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, California, USA.
Miao ZhangDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, California, USA.
Reza MehvarDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, California, USA.ORCID https://orcid.org/0000-0002-1770-0391
Chapman University · US

Funding

Development of SK channel modulators as therapeutic agents for ataxiaR33NS101182 · NINDS · CHAPMAN UNIVERSITY · PI BEZPROZVANNY, ILYA B, ZHANG, MIAO · 2021 to 2021
$723k
NIH HHS 4R33NS101182-03NINDS NIH HHS R33 NS101182
6 · The paper itself

Abstract

rationaleThere is currently no treatment for spinocerebellar ataxias (SCAs), which are a group of genetic disorders that often cause a lack of coordination, difficulty walking, slurred speech, tremors, and eventually death. Activation of K

methodsMouse plasma samples (10 μL) containing various concentrations of 2q were subjected to protein precipitation in the presence of a structurally similar internal standard (IS). Subsequently, the analytes were separated on a C

resultsThe calibration standards were linear (r

conclusionsThe developed assay is suitable for preclinical pharmacokinetic-pharmacodynamic studies of 2q as a potential drug candidate for ataxias.

Indexed as

PlasmaTandem Mass SpectrometryAnimalsChromatography, High Pressure LiquidChromatography, LiquidMiceReproducibility of Results

Identifiers

PMID37184249
PMCPMC10330529
OpenAlexW4376613235

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.